📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 4.2.2 — Pharmacokinetics (OBX-319)

Document ID: M4-2.2
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M3(R2), S6(R1), S5(R3), S7A; S2/S1/S7B addressed by waiver rationale

4.2.2 Pharmacokinetics — OBX-319

Relevant species: cynomolgus monkey as the sole pharmacologically relevant species (no rodent cross-reactivity). OBX-319 is a humanised bispecific IgG1 monoclonal antibody, and both of its binding arms — the anti-CD19 paratope and the anti-CD20 paratope — engage epitopes that are conserved between human and cynomolgus monkey, whereas neither target is bound in mouse, rat, rabbit, or dog. The monkey is therefore the only species in which target-mediated disposition and on-target B-cell pharmacology can be reproduced, and it was selected for all pivotal pharmacokinetic (PK) and toxicokinetic (TK) characterisation in accordance with ICH S6(R1). Rodent PK studies would not be pharmacologically informative and were not conducted; the nonclinical PK dataset is interpreted together with the human PK data in Module 5.3.

OBX-319 is produced by recombinant CHO cell culture, and its disposition follows the principles established for intact immunoglobulins rather than for small molecules. Subcutaneous absorption with typical IgG bioavailability; target-mediated drug disposition (TMDD) producing non-linear PK at low concentrations; distribution largely confined to plasma and interstitial fluid; elimination by proteolytic catabolism and (in the target-mediated component) receptor-mediated clearance. Classical small-molecule ADME (mass balance, CYP/transporter) is not applicable to an intact IgG.

Two elimination pathways operate in parallel. A linear, non-saturable pathway reflects FcRn-protected proteolytic catabolism common to endogenous IgG; a non-linear, saturable pathway arises from high-affinity binding to CD19 and CD20 on B lymphocytes, followed by receptor-mediated internalisation and degradation. Because OBX-319 is bispecific, either arm can contribute to target-mediated clearance, and the analyte and modelling strategy were designed to reflect disposition of the intact, dual-armed molecule rather than of a monospecific fragment.

Bioanalytical strategy. Serum OBX-319 was quantified with validated ligand-binding assays (electrochemiluminescence/ELISA format). Because the molecule is bispecific, the analyte definition and reagent design were set to capture the intact antibody bearing both functional arms, distinguishing active drug from any degraded or single-arm species and confirming that chain pairing is maintained in circulation. Anti-drug antibody (ADA) and neutralising-antibody responses were characterised with a tiered screen / confirm / titre assay strategy. Bioanalysis supporting the pivotal TK was conducted under GLP using validated methods consistent with the principles of ICH M10; exploratory nonclinical PK used fit-for-purpose qualified assays.

Absorption, distribution, elimination

Systemic exposure after subcutaneous administration was characterised, and toxicokinetics were integrated into the repeat-dose toxicity studies to establish exposure at the no-observed-adverse-effect level. TK were embedded in the cynomolgus repeat-dose study (up to 26 weeks) with serial sampling to estimate Cmax, AUC, and accumulation at the NOAEL, and with concurrent ADA sampling to support interpretation of any exposure loss.

Absorption. After subcutaneous administration OBX-319 is absorbed slowly, predominantly by convective transport through the lymphatics into the systemic circulation, giving a delayed time to maximum concentration and a bioavailability in the range typical of subcutaneously administered IgG1 antibodies. Exposure rose with dose; at the higher exposures achieved in the toxicity studies the target-mediated pathway is largely saturated and disposition approaches dose-proportional, IgG-like behaviour, whereas at low concentrations absorption is followed by more rapid, non-linear elimination.

Distribution. Consistent with an intact ~150 kDa immunoglobulin, the apparent volume of distribution is small, approximating plasma volume with limited extravascular penetration into interstitial fluid, and OBX-319 does not distribute intracellularly other than through target engagement. The principal distribution determinant is the antigen sink formed by CD19/CD20-expressing B cells in peripheral blood, spleen, lymph nodes, and bone marrow. Tissue cross-reactivity assessment on frozen human and cynomolgus tissue panels showed staining confined to B-lineage and lymphoid compartments, consistent with the intended dual targets and supporting the distribution interpretation. As a humanised IgG1, OBX-319 is subject to FcRn-mediated transplacental transfer in later gestation; this property is addressed in the enhanced pre-/post-natal development study (Module 4.2.3) rather than by dedicated distribution studies.

Metabolism and excretion. As with endogenous IgG, OBX-319 is cleared by proteolytic catabolism to peptides and amino acids within the reticuloendothelial system and within target cells following receptor-mediated internalisation; FcRn salvage of pinocytosed antibody protects the linear pathway and confers the prolonged terminal half-life characteristic of a humanised IgG1. There is no cytochrome-P450 or transporter-mediated metabolism, no discrete circulating metabolites requiring identification, and no meaningful renal or biliary excretion of intact antibody, which is too large for glomerular filtration. Mass-balance, metabolite-identification, and excretion studies are therefore not applicable and were not performed.

Target-mediated disposition and PK/PD relationship. The non-linear component of clearance is time-varying: as OBX-319 depletes its own target pool the antigen sink contracts, target-mediated clearance falls, and total systemic clearance decreases over the course of treatment (non-stationary PK). This behaviour mirrors the pharmacodynamic effect — near-complete peripheral CD19+ B-cell depletion on the active arms (approximately 210 to approximately 7 cells/µL) with essentially unchanged counts on placebo — and was described with an integrated TMDD / PK–PD model that links serum exposure to the extent and duration of B-cell depletion. The model supports the exposures evaluated across the clinical dose levels in OBX319-301 (OBX-319 High, OBX-319 Low, Placebo).

Immunogenicity and pharmacokinetics. Treatment-emergent ADA can accelerate clearance and reduce exposure, so TK were interpreted alongside ADA status and any exposure decrement was assessed against the tiered binding/neutralising assay results. The immunogenicity of a humanised antibody in the cynomolgus monkey is not predictive of clinical immunogenicity; nonclinical ADA data are used only to interpret animal exposure and are not extrapolated to project human ADA rates.

Pharmacokinetic drug interactions. Direct CYP/transporter-based interactions are not expected for an intact immunoglobulin, and dedicated nonclinical interaction studies are not warranted. Consistent with therapeutic-protein interaction principles, the theoretical potential for cytokine-mediated modulation of CYP enzymes in the inflammatory SLE setting was considered; a targeted B-cell-depleting antibody is not anticipated to produce clinically meaningful changes, and the question is addressed in the clinical pharmacology assessment (Modules 2.7.2 and 5.3).

Interspecies translation. Cynomolgus PK/TK, together with in vitro potency and dual-target binding data, informed projection of human exposure and dose selection on a minimum-anticipated-biological-effect-level basis appropriate to a B-cell-depleting antibody, and underpins the exposure-based safety margins reported in Module 4.2.3.

GLP compliance. Toxicokinetic assessments were conducted under GLP within the pivotal toxicity studies; standalone characterisation studies (e.g. distribution) were non-GLP. Bioanalytical methods supporting the pivotal TK were validated, while exploratory nonclinical PK employed fit-for-purpose qualified assays consistent with their supportive role.

Governing guidelines: ICH M3(R2), S6(R1), S5(R3), S7A; S2/S1/S7B addressed by waiver rationale.